Biodesix, Inc.

Category: Content
Type: Blog Article

Generated 2 days ago

New blog articles detected

  • Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

    Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1 ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells   Poster Title: Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.   Poster Session Date/Time: February 24, 11:30AM – 1:00PM; 5:30PM-6:30PM   Presenting Author: Hestia Mellert, Ph.D […] Th...

Biodesix, Inc.

Category: Content
Type: Blog Article

Generated 2 weeks ago

New blog articles detected

  • Immuno-Oncology360 February 1-3, New York, NY

    The post Immuno-Oncology360 February 1-3, New York, NY appeared first on Biodesix.

  • Clin-TOF Successfully Integrated into VeriStrat® Workflow

    Study Results, Presented at MSACL, Advance Biodesix®/Bioyong Agreement Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat® test in Greater China. The data were presented in a poster at the ninth annual conference of the Association […] The post Clin-TOF ...

  • Patient Video: Victoria’s Story

    Video: Victoria, stage 4 lung cancer patient, discusses the impact that liquid biopsy testing had on her treatment and outlook. The post Patient Video: Victoria’s Story appeared first on Biodesix.

  • Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

    US $38M; Potential Expansion into Other Asia/Pacific Countries, Additional Liquid Biopsy Products Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test, a precision medicine diagnos...

  • Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

    “VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy. The post Tests Demonstrate Ability to Stratify Patients...

  • Biodesix® Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

    VeriStrat® Test Shown To Have Clinical Utility in Predicting Overall Survival of Afatinib-Treated Patients With Lung Cancer   December 13, 2016, Boulder, Colorado… Two studies demonstrating the clinical utility of the VeriStrat® test in the management of patients with non-small cell lung cancer (NSCLC) were presented last week at the 17th World Conference on Lung […] The post Biodesix® Tests Demon...

  • Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

    Biodesix won the award for “Innovative Company of the Year” last night at the 2016 IQ Awards and Innovation Summit presented by BizWest Media. The other finalists in the category were Fort Collins-based Madwire and n.io of Broomfield. “We are really in the business of helping cancer patients to determine the most effective treatment for […] The post Biodesix® Named Innovative Company of the Year a...

  • Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

    Actionable mutation results from a single blood draw, 72 hour turnaround time   February 2, 2017, Boulder, CO….Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRAS, BRAF mutations; and EML4-ALK fusions. GeneStrat is a non-invasive, […] The post Genestrat Liquid Bi...

  • 3rd Annual Moffitt Anatomic Pathology Symposium, February 2-5, Sarasota, FL

    The post 3rd Annual Moffitt Anatomic Pathology Symposium, February 2-5, Sarasota, FL appeared first on Biodesix.

  • ASCO-SITC February 23-27, Orlando, FL

    The post ASCO-SITC February 23-27, Orlando, FL appeared first on Biodesix.

Biodesix, Inc.

Category: Content
Type: Blog Article

Generated 4 months ago

New blog articles detected

Biodesix, Inc.

Category: Content
Type: Blog Article

Generated 5 months ago

Biodesix, Inc.

Category: Content
Type: Blog Article

Generated 5 months ago

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in